Fulgent Genetics Inc. (FLGT)
NASDAQ: FLGTHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FLGT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $673.89M
- EPS (TTM)
- -$3.10
- Dividend yield
- None
- 52-week range
- 13.46 – 31.04
- Day range
- 23.88 – 24.79
- Volume / Avg
- 322.97K / 330.28K
- Beta
- —
- Shares outstanding
- 27.94M
52-week range
FLGT stock today
On Nov 20, FLGT ended the session at $24.12, shedding $0.66 (2.66%), versus the S&P 500's 3.70% decline. Shares are 22.3% below their 52-week high of $31.04, set on Nov 25, 2025 and 79.2% above the 52-week low of $13.46, in the middle of the past year's range. FLGT is down 8.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 19.6%.
Fulgent Genetics has posted a net loss over the last twelve months (EPS of -$3.10), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Fulgent Genetics
Company profileFulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Ming Hsieh
- Headquarters
- El Monte, CA
- Employees
- 1,315
- IPO year
- 2016
- Website
- fulgentgenetics.com
Financial highlights
Full financialsIn fiscal 2025, Fulgent Genetics generated $322.7 million in revenue, up 13.8% from fiscal 2024. Fulgent Genetics reported a net loss of $60.5 million, compared with a loss of $42.7 million a year earlier. Gross margin was 40.6% (up from 37.8%) and operating margin -28.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $322.67M | $283.47M | $289.21M | $618.97M | $992.58M |
| Growth | +13.83% | -1.99% | -53.27% | -37.64% | +135.37% |
| Net income | $-60.51M | $-42.71M | $-167.82M | $143.40M | $507.36M |
| EPS (diluted) | $-1.97 | $-1.41 | $-5.63 | $4.63 | $16.38 |
Analyst forecast
ForecastConsensus (1 analysts)
hold
Avg. price target
$25.00+3.65%
- Strong buy 0
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.48 vs $1.00
- Surprise
- -148.00%
FLGT news
All FLGT news- Fulgent Genetics, Inc. Enters Lease for 44,644 Square Feet in Needham, MassachusettsNasdaq
- Fulgent: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Fulgent Genetics Consensus Price Target Raised 31.58% to $25.50Nasdaq
- Fulgent Genetics Non-GAAP EPS of -$0.09 beats by $0.56, revenue of $90.4M beats by $4.1MSeeking Alpha
- Fulgent Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026Business Wire
Fulgent Genetics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| YDESYD Bio Limited | 4.83 | +5.92% | $342.12M | vs FLGT |
| CSTLCastle Biosciences Inc. | 32.86 | -1.63% | $1.01B | vs FLGT |
| FRNMFreenome Inc. | 9.36 | -5.69% | $1.04B | vs FLGT |
| TLSITriSalus Life Sciences Inc. | 2.32 | +6.67% | $143.14M | vs FLGT |
| BNRBurning Rock Biotech Limited ADR | 13.24 | -0.60% | $139.63M | vs FLGT |
| KEQUKewaunee Scientific Corporation | 33.55 | -2.75% | $97.14M | vs FLGT |
| XGNExagen Inc. | 3.61 | -5.00% | $92.10M | vs FLGT |
| BDSXBiodesix Inc. | 7.56 | -8.92% | $83.83M | vs FLGT |
Indexes, lists and sector
Fulgent Genetics stock FAQ
What is Fulgent Genetics's stock price today?
FLGT last traded at $24.12 as of Nov 20, 4:00 PM EST, down 2.66% on the day. Prices are delayed at least 15 minutes.
Who is Fulgent Genetics's CEO?
Mr. Ming Hsieh is the chief executive officer of Fulgent Genetics Inc., which has about 1,315 employees.
What is the FLGT 52-week high?
The 52-week high for FLGT is $31.04 and the 52-week low is $13.46. The stock is currently 22.3% below its high.